Quarterly ResultAug 6, 2026, 08:22 AM
Aurinia Q2 Revenue $83.2M, Net Income $37.4M; Acquires Kezar
AI Summary
Aurinia Pharmaceuticals reported strong financial results for the second quarter and first half of 2026, with significant increases in revenue, net income, and EPS. The company also completed the acquisition of Kezar Life Sciences, Inc. for $51.6 million in cash. Additionally, Aurinia continued its share repurchase program, buying back 2.5 million shares for $38.1 million during the quarter.
Key Highlights
- Acquired Kezar Life Sciences for $51.6 million cash on May 11, 2026.
- Total revenue for Q2 2026 increased to $83.2 million from $70.0 million YoY.
- Net income for Q2 2026 rose to $37.4 million from $21.5 million YoY.
- Diluted EPS for Q2 2026 increased to $0.28 from $0.16 YoY.
- Cash, cash equivalents, and restricted cash grew to $179.8 million as of June 30, 2026.
- Repurchased 2.5 million common shares for $38.1 million in Q2 2026.
- Cash flows from operating activities for the six months ended June 30, 2026, were $85.1 million.
Price Impact
More from AUPH